This is the authors' abstract. We don't add key points for this paper.
The use of long-acting basal insulin analogs is a recommended strategy in older people with diabetes because of their lower risk of hypoglycemia compared to intermediate-acting insulins. In this article, we review the results from recent clinical trials of second-generation basal insulin preparations. We conclude that, although these preparations have improved the management of insulin-requiring older people with type 2 diabetes, there is a need for additional and more specific studies to address the complexities of hyperglycemia management in this population.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Cersósimo et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: